Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.pone.0249349 http://scihub22266oqcxt.onion/10.1371/journal.pone.0249349 33831046!8031323!33831046     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PLoS+One 2021 ; 16 (4): e0249349 Nephropedia Template TP {{tp|p=33831046|t=2021. What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak |pdf=|usr=}}{{33831046}} gab.com Text What about tocilizumab A retrospective study from a NYC Hospital during the COVID-19 outbreak JO: PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=33831046 #FOAvip BACKGROUND: Tocilizumab, an interleukin-6 receptor blocker, has been used in the inflammatory phase of COVID-19, but its impact independent of corticosteroids remains unclear in patients with severe disease. METHODS: In this retrospective analysis of patients with COVID-19 admitted between March 2 and April 14, 2020 to a large academic medical center in New York City, we describe outcomes associated with tocilizumab 400 mg (without methylprednisolone) compared to a propensity-matched control. The primary endpoints were change in a 7-point ordinal scale of oxygenation and ventilator free survival, both at days 14 and 28. Secondary endpoints include incidence of bacterial superinfections and gastrointestinal perforation. Primary outcomes were evaluated using t-test. RESULTS: We identified 33 patients who received tocilizumab and matched 74 controls based on demographics and health measures upon admission. After adjusting for illness severity and baseline ordinal scale, we failed to find evidence of an improvement in hypoxemia based on an ordinal scale at hospital day 14 in the tocilizumab group (OR 2.2; 95% CI, 0.7-6.5; p = 0.157) or day 28 (OR 1.1; 95% CI, 0.4-3.6; p = 0.82). There also was no evidence of an improvement in ventilator-free survival at day 14 (OR 0.8; 95% CI, 0.18-3.5; p = 0.75) or day 28 (OR 1.1; 95% CI, 0.1-1.8; p = 0.23). There was no increase in secondary bacterial infection rates in the tocilizumab group compared to controls (OR 0.37; 95% CI, 0.09-1.53; p = 0.168). CONCLUSIONS: There was no evidence to support an improvement in hypoxemia or ventilator-free survival with use of tocilizumab 400 mg in the absence of corticosteroids. No increase in secondary bacterial infections was observed in the group receiving tocilizumab. Twit Text FOAVip What about tocilizumab A retrospective study from a NYC Hospital during the COVID-19 outbreak ????PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=33831046 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33831046 #FOAvip English Wikipedia <ref>{{Cite pmid|33831046}}</ref> What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak #MMPMID33831046 Mehta M; Purpura LJ; McConville TH; Neidell MJ; Anderson MR; Bernstein EJ; Dietz DE; Laracy J; Gunaratne SH; Miller EH; Cheng J; Zucker J; Shah SS; Chaudhuri S; Gordillo CA; Patel SR; Guo TW; Karaaslan LE; Reshef R; Miko BA; Bathon JM; Pereira MR; Uhlemann AC; Yin MT; Sobieszczyk ME PLoS One 2021[]; 16 (4): e0249349 PMID33831046show ga BACKGROUND: Tocilizumab, an interleukin-6 receptor blocker, has been used in the inflammatory phase of COVID-19, but its impact independent of corticosteroids remains unclear in patients with severe disease. METHODS: In this retrospective analysis of patients with COVID-19 admitted between March 2 and April 14, 2020 to a large academic medical center in New York City, we describe outcomes associated with tocilizumab 400 mg (without methylprednisolone) compared to a propensity-matched control. The primary endpoints were change in a 7-point ordinal scale of oxygenation and ventilator free survival, both at days 14 and 28. Secondary endpoints include incidence of bacterial superinfections and gastrointestinal perforation. Primary outcomes were evaluated using t-test. RESULTS: We identified 33 patients who received tocilizumab and matched 74 controls based on demographics and health measures upon admission. After adjusting for illness severity and baseline ordinal scale, we failed to find evidence of an improvement in hypoxemia based on an ordinal scale at hospital day 14 in the tocilizumab group (OR 2.2; 95% CI, 0.7-6.5; p = 0.157) or day 28 (OR 1.1; 95% CI, 0.4-3.6; p = 0.82). There also was no evidence of an improvement in ventilator-free survival at day 14 (OR 0.8; 95% CI, 0.18-3.5; p = 0.75) or day 28 (OR 1.1; 95% CI, 0.1-1.8; p = 0.23). There was no increase in secondary bacterial infection rates in the tocilizumab group compared to controls (OR 0.37; 95% CI, 0.09-1.53; p = 0.168). CONCLUSIONS: There was no evidence to support an improvement in hypoxemia or ventilator-free survival with use of tocilizumab 400 mg in the absence of corticosteroids. No increase in secondary bacterial infections was observed in the group receiving tocilizumab. |*Bacterial Infections/etiology/mortality[MESH] |*COVID-19 Drug Treatment[MESH] |*COVID-19/mortality[MESH] |*Disease Outbreaks[MESH] |*Hospitals, Teaching[MESH] |*SARS-CoV-2[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects[MESH] |Disease-Free Survival[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |New York City/epidemiology[MESH] |Respiration, Artificial[MESH] |Retrospective Studies[MESH]What about tocilizumab? A retrospective study from a NYC Hospital duri(epmc).pdf DeepDyve Pubget Overpricing